Dayvigo (lemborexant) is a prescription medication used to treat insomnia characterized by difficulties with sleep onset and/or sleep maintenance [1]. It is a dual orexin receptor antagonist (DORA) that works by blocking the wake-promoting actions of orexin neuropeptides [1][2].
How is Dayvigo taken?
Dayvigo is taken orally, typically as a single dose at bedtime [1]. It is available in tablet form at dosages of 5 mg and 10 mg [1][3]. Patients should not take Dayvigo if they have not had at least 7 hours to sleep before they need to wake up [1].
What are the potential side effects of Dayvigo?
Common side effects of Dayvigo include drowsiness, somnolence, and headache [1]. More serious, though less common, side effects can include sleep paralysis, hypnopompic hallucinations, and abnormal dreams [1]. Patients are advised to avoid activities requiring full alertness, such as driving or operating machinery, until they know how Dayvigo affects them, as it can impair daytime functioning [1].
When does the patent for Dayvigo expire?
Information on the patent expiry for Dayvigo can be found on DrugPatentWatch.com. Patents for drugs can be complex and may involve multiple patents covering different aspects of the drug, such as composition of matter, methods of use, and manufacturing processes [4].
Who makes Dayvigo?
Dayvigo is manufactured by Eisai Inc. [1].
How does Dayvigo compare to other insomnia treatments?
Dayvigo belongs to a class of medications known as orexin receptor antagonists, which differ in their mechanism of action from older insomnia treatments like benzodiazepines and non-benzodiazepine hypnotics (e.g., Ambien, Lunesta) [2][5]. Orexin receptor antagonists target the wakefulness system, while other classes often act as sedatives by enhancing inhibitory neurotransmission [2][5]. This difference in mechanism may lead to a different side effect profile and potential for dependence [2][5].
What clinical data supports Dayvigo's use?
Clinical trials for Dayvigo demonstrated its efficacy in reducing the time it takes to fall asleep and in improving total sleep time [1]. The recommended starting dose for Dayvigo is 5 mg for certain populations, including women and individuals with mild to moderate hepatic impairment [1].
What precautions should patients take with Dayvigo?
Patients should discuss their full medical history with their doctor before starting Dayvigo, particularly any history of liver disease, kidney disease, or lung disease [1]. Dayvigo is a central nervous system depressant and can cause additive effects when taken with alcohol or other CNS depressants [1].
Sources:
[1] https://www.dayvigo.com/
[2] https://www.drugpatentwatch.com/blog/orexin-antagonists-a-new-era-in-insomnia-treatment
[3] https://www.dayvigo.com/dosaging-and-how-to-take
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/blog/understanding-drug-patents-and-exclusivity